ClinicalTrials.gg
RecruitingNCT07151690AL-003Updated Jul 23, 2026

BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis

A Phase 2 interventional study of anti-BCMA/CD3 bispecific antibody in Systemic Light Chain Amyloidosis, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Amyloidosis with a site in China — 21 open to participants now, 25 under way, 3 of them phase 3. Amyloidosis · China.

Planned enrollment
20th of 24
21 · median 53
Started
2025
with 7 others
Phase 2
7 of 32
3 open now
Primary completion
2026-12
later than 10 of 24 live
Registered
22nd of 32
by date

Among the 32 studies in Amyloidosis with a site in China, this one is the 20th largest by planned enrollment of the 24 interventional ones that give a count, is one of 8 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 10 of the 24 other live ones, and was the 22nd registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

21 of the 32 studies in Amyloidosis with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Amyloidosis with a site in China, or all of them as a file.
02

Study summary

This is a prospective, single-arm, single-center clinical study designed to evaluate the efficacy and safety of low-dose BCMA/CD3 bispecific antibody (CM336) in patients newly diagnosed with systemic light chain (AL) amyloidosis.

03

Conditions studied

  • Systemic Light Chain Amyloidosis

Browse trials for

Keywords

  • Systemic Light Chain Amyloidosis
  • BCMA/CD3 bispecific antibody
  • CM336
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. The patient is informed of and voluntarily signs the form (ICF).
  2. Age ≥18 years, regardless of sex.
  3. Confirmed diagnosis of primary light-chain (AL) amyloidosis, in accordance with the Guidelines for the Diagnosis and Treatment of Systemic Light-chain Amyloidosis (2021 Revision).
  4. at screening, defined as:

    • Difference between involved and uninvolved free light chains (dFLC) ≥50 mg/L, or
    • Serum involved free light chain ≥50 mg/L with an abnormal κ:λ ratio.
  5. performance status ≤2.
  6. Adequate organ function within 3 days prior to the first dose of the drug, meeting all of the following criteria:

    i. (ANC) ≥1.0 × 10⁹/L, with no granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) administration within 7 days, and no pegylated G-CSF administration within 14 days prior to testing; ii. (Hb) ≥75 g/L, with no whole blood or red blood cell transfusion within 7 days prior to testing; iii. count ≥70 × 10⁹/L, with no whole blood transfusion, platelet transfusion, or thrombopoietin receptor agonist treatment within 7 days prior to testing; iv. Hepatic function: (ALT) ≤3 × (ULN), aspartate aminotransferase (AST) ≤3 × ULN, total ≤2 × ULN (subjects with Gilbert's syndrome are eligible if direct bilirubin ≤2 × ULN); v. Coagulation: (INR) or activated partial thromboplastin time (APTT) ≤1.5 × ULN; vi. Renal function: estimated (eGFR) ≥20 mL/min/1.73 m², calculated using the CKD-EPI equation.

  7. Male and female patients of , and their partners, must agree to use effective methods deemed appropriate by the investigator throughout the treatment period and for at least 3 months thereafter.
  8. Male patients must agree not to donate sperm from the screening period until 90 days after the last dose of the investigational drug.
  9. The patient must be willing and able to comply with all study procedures and follow-up visits.
  10. Women not of childbearing potential are eligible for enrollment. Women of childbearing potential must have a negative serum or urine β-hCG pregnancy test at screening.

Note:

A woman of childbearing potential is defined as a sexually mature woman who has not undergone surgical sterilization (e.g., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) and has not been for at least 12 consecutive months for reasons other than medical treatment. Women using oral contraceptives or intrauterine devices are considered of childbearing potential. Male subjects (including those who have undergone vasectomy) must agree to use condoms during sexual intercourse with women of childbearing potential and must have no plans to father a child from the time of signing the ICF until 3 months after the last dose of study treatment.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    BsAbs-treatment group

    Treatment involves a 12-cycle course of weekly subcutaneous CM336, with step-up dosing during the first week (3 mg on Day 1, 20 mg on Day 4, and 40 mg weekly from Day 8 onward). Dose frequency may be reduced to every two weeks in patients achieving ≥VGPR after 4 cycles.

    Drug: anti-BCMA/CD3 bispecific antibody

Interventions

  • Druganti-BCMA/CD3 bispecific antibody

    Drug page: Anti-BCMA/CD3 Bispecific Monoclonal AntibodyStudies of Anti-BCMA/CD3 Bispecific Monoclonal AntibodyAnti-BCMA/CD3 Bispecific Monoclonal Antibody pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    CM336 is a bispecific T-cell engager targeting B-cell maturation antigen (BCMA) and CD3. In this study, CM336 is administered subcutaneously with a step-up dosing strategy in Cycle 1 (3 mg Day 1, 20 mg Day 4, 40 mg Day 8 and onwards weekly). Patients who achieve ≥VGPR by Cycle 4 may switch to 80 mg every two weeks from Cycle 5. The total treatment duration is up to 12 cycles (28 days per cycle), with follow-up for safety and efficacy endpoints including hematologic and organ response.

06

What researchers measure

Primary outcomes

  1. Rate of Hematologic Very Good Partial Response (VGPR) or Better

    Proportion of participants achieving a hematologic response of VGPR or better (≥VGPR) of anti-BCMA/CD3 bispecific antibody (CM336), assessed using consensus criteria for AL amyloidosis hematologic response.

    Time frame: 4 months

  2. Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Safety will be assessed by monitoring the incidence, nature, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs), adverse events of special interest (AESIs) such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), graded according to NCI CTCAE v5.0 and ASTCT criteria. Dose interruptions, modifications, or discontinuations due to toxicity will also be recorded.

    Time frame: From the first dose through 30 days after the last dose, up to approximately 24 months.

Secondary outcomes

  1. Time to First Hematologic Response (TTR)

    Time frame: From the first dose until the best hematologic response (≥PR) is achieved, assessed up to approximately 24 months.

  2. Best Hematologic Response Achieved

    The deepest hematologic response (e.g., PR, VGPR, CR, or sCR) observed at any time during the treatment period.

    Time frame: From the first dose until the best hematologic response (≥PR) is achieved, assessed up to approximately 24 months.

  3. Duration of Hematologic Response (DOR)

    Time from the first documented hematologic response to disease progression or death, whichever occurs first.

    Time frame: From the date of first documented hematologic response to the date of disease progression or death, whichever occurs first, up to approximately 24 months.

  4. Overall Response Rate (ORR)

    Time frame: The overall response rate (ORR) was evaluated at the end of cycle 4, 6, and 12 (28 days per cycle).

  5. Progression-Free Survival (PFS)

    defined as the time from the date of treatment to the date of first documentation of hematologic disease progression, or organ progression, or death due to any cause.

    Time frame: From the first dose to progression from any cause, up to approximately 36 months.

  6. Overall Survival (OS)

    Time frame: From the first dose to death from any cause, up to approximately 36 months.

  7. Minimal Residual Disease (MRD) Negativity Rate

    Minimal residual disease (MRD) negativity rate:MRD negativity assessed in bone marrow.

    Time frame: From baseline to 24 months, assessed at predefined response evaluation time points.

  8. Organ Response

    Assess Organ Responses Based on Standard Criteria Included in Protocol among patients with organ involvement

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 24 phase 2 interventional studies under Amyloidosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 64. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Sep 3, 2025
StartActual
Sep 4, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2027
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07151690
Responsible party
Sponsor
First posted
Sep 3, 2025
Start date
Sep 4, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jul 23, 2026

Study contacts

Gang An, MD
Contact
angang@ihcams.ac.cn
13502181109

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-BCMA/CD3 Bispecific Monoclonal Antibody

Start the discussion